Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance
Open accessThe DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.
Abstract
Angiopoietin-like protein (ANGPTL)3 regulates plasma lipids by inhibiting LPL and endothelial lipase (EL). ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway and represents a promising therapeutic approach for individuals with homozygous familial hypercholesterolemia due to LDLR mutations. Yet, how ANGPTL3 regulates LDL-C levels is unknown. Here, we demonstrate in hyperlipidemic humans and mice that ANGPTL3 controls VLDL catabolism upstream of LDL. Using kinetic, lipidomic, and biophysical studies, we show that ANGPTL3 inhibition reduces VLDL-lipid content and size, generating remnant particles that are efficiently removed from the circulation. This suggests that ANGPTL3 inhibition lowers LDL-C by limiting LDL particle production. Mechanistically, we discovered that EL is a key mediator of ANGPTL3's novel pathway. Our experiments revealed that, although dispensable in the presence of LDLR, EL-mediated processing of VLDL becomes critical for LDLR-independent particle clearance. In the absence of EL and LDLR, ANGPTL3 inhibition perturbed VLDL catabolism, promoted accumulation of atypical remnants, and failed to reduce LDL-C. Taken together, we uncover ANGPTL3 at the helm of a novel EL-dependent pathway that lowers LDL-C in the absence of LDLR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. EL is necessary for the LDLR-independent LDL-C-lowering effect upon ANGPTL3 inhibition. A: Inhibition of ANGPTL3 lowers serum phospholipids in Ldlr−/− mice on chow diet 4 days after ANGPTL3 mAb or control mAb (n = 5 mice per group, 10 mg/kg mAb) (left). Mean ± SEM are shown. P-values are from unpaired two-tailed Student’s t-test. Serum lipid distribution in Ldlr−/− mice showing ANGPTL3 mAb lowers phospholipids across all lipoproteins. Pooled serum [n = 6 mice in control (Ctrl) mAb group; n = 5 mice in ANGPTL3 mAb group] was fractionated by FPLC, and phospholipid levels were measured enzymatically in each fraction (right). B: Serum PLTP activity in Ldlr−/− mice on chow diet 6 days before (baseline) and 7 days after ANGPTL3 mAb or control mAb (n = 6 mice per group, 10 mg/kg mAb). Mean ± SEM are shown. P-values are from two-way ANOVA with Sidak correction posttest relative to control. C: Serum lipid distribution of chow-fed WT (n = 10), Lipg−/− (n = 12), Ldlr−/− (n = 23), and Lipg−/−Ldlr−/− (n = 24) mice (left). Pooled serum from each group of mice was separated by HPLC, and cholesterol levels were measured enzymatically. Ratio showing VLDL and LDL APOB-particle numbers in Ldlr−/− and Lipg−/−Ldlr−/− mice (right). D: Nonfasted serum cholesterol of WT and Lipg−/− mice on chow (baseline), after 2 weeks on HFD (HFD baseline), and 6 days after ANGPTL3 or control mAb dose (25 mg/kg) while on HFD. Mean ± SEM are shown (n = 15 mice in WT Ctrl mAb group, n = 16 mice in all other groups). P-values are from two-way ANOVA with Tukey correction posttest. E: Nonfasted serum lipids of Ldlr−/− and Lipg−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown (n = 14 mice in each Ldlr−/− group, n = 17 mice in Lipg−/−Ldlr−/− Ctrl mAb group, n = 18 mice in Lipg−/−Ldlr−/− ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest.](https://figures.cochat.ai/paper-figures/6312bc63bec6404bae3183ad5bf2144c/angiopoietin-like-protein-3-governs-ldl-cholesterol-levels-through-endothelial-figure-1.jpg)


![Fig. 4. ANGPTL3 inhibition promotes VLDL processing and clearance. A: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) and LDL (right) isolated from Ldlr−/− or Lipg−/−Ldlr−/− mice and injected into Ldlr−/− mice (VLDL from Ldlr−/−: n = 10 recipient mice; VLDL from Lipg−/−Ldlr−/−: n = 9 recipient mice). B: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) or LDL (right) isolated from Apoe−/− mice after 2 weekly injections of ANGPTL3 mAb or control mAb and injected into Apoe−/− mice (n = 10 mice per group). A, B: The percentage of injected CE-label remaining at each timepoint was determined using the value obtained at 30 s as starting point. Mean ± SEM are shown for each timepoint. P-values from two-way ANOVA with Sidak correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001. The half-life was calculated from the decay curve of [3H]CE activity plotted against time. All mice were on chow diet. C, D: NMR analysis of human lipoproteins following ANGPTL3 inhibition with evinacumab (ANGPTL3 mAb). Hyperlipidemic individuals were administered ANGPTL3 mAb or control mAb (phase 1 single ascending dose clinical study) (28), and serum was collected at the indicated timepoints. Mean ± SEM are shown for each timepoint (n = 18 in placebo; n = 10 in 5 mg/kg iv; n = 9 in 10 mg/kg iv; n = 11 in 20 mg/kg iv; n = 12 in 150 mg sc; and n = 9 in 250 mg sc groups). Human VLDL/chylomicron and LDL concentration (C) and particle size analysis by NMR (D). P-values are from two-way ANOVA with Tukey correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to placebo (color of asterisks indicates relevant group); #P < 0.0001 regarding all ANGPTL3 mAb groups relative to placebo; &P < 0.0001 regarding all intravenously administered ANGPTL3 mAb groups relative to placebo.](https://figures.cochat.ai/paper-figures/e7e016c17f3546eabd59b703a97b776c/angiopoietin-like-protein-3-governs-ldl-cholesterol-levels-through-endothelial-figure-4.jpg)
![Fig. 5. ANGPTL3 inhibition lowers LDL-C independently of several lipoprotein receptors. A: Nonfasted serum lipids of Ldlr−/− and Sdc1−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown [n = 7 mice in Sdc1−/−Ldlr−/− control (Ctrl) mAb group, n = 8 mice in all other groups]. P-values are from two-way ANOVA with Sidak correction posttest. HPLC analysis shown at right. B, C: The effect of ANGPTL3 inhibition on serum lipids in ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice on chow diet. Nonfasted serum was collected from Sdc1−/−Ldlr−/− mice (baseline). Scarb1, Scarb1+Lrp1, or control ASOs (25 mg/kg) were administered twice weekly by subcutaneous injections, for a total of 10 doses. Two once-weekly doses of ANGPTL3 or control mAb (10 mg/kg) were administered after first six doses of ASO (ASO pre-mAb). Seven days after the second mAb dose, serum was collected and livers were harvested (ASO, post-mAb). Mean lipid levels ± SEM are shown in B; HPLC analysis of serum is shown in C (n = 8 mice in all groups except n = 7 in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest. D: Hepatic knockdown efficiency upon ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice, corresponding to the study shown in B and C. Mean ± SEM are shown (n = 8 mice per group except n = 7 mice in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from one-way ANOVA with Tukey correction posttest. ****P < 0.0001 for Scarb1 ASO groups or Lrp1+Scarb1 ASO groups relative to control ASO groups.](https://figures.cochat.ai/paper-figures/6bd4c3bf1dc54810b0b887dd47f783df/angiopoietin-like-protein-3-governs-ldl-cholesterol-levels-through-endothelial-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, ANGPTL3 inhibition accelerates triglyceride-rich lipoprotein processing and reduces LDL precursors while enhancing HDL catabolism, accounting for concurrent LDL-C reduction and modest HDL-C decrease (Zhang, 2021; Chen et al., 2024; Adam et al., 2020; Wang et al., 2015; Yasuda et al., 2010; Hooper and Burnett, 2013).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Adam et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Extensive studies in animal models suggest that the LDL-C lowering effect of evinacumab is not dependent on a number of other receptors or ligands, such as apolipoprotein E, LDLR-related protein 1, and syndecan 1, which are known to affect LDL or its precursors,6 and SR-BI.10”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Recent reports of studies in mice suggest that EL is required for ANGPTL3 inhibition to reduce LDL-C levels in absence of a functional LDLR.10,11”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“These studies, in mice lacking both LDLR and EL, support the importance of the ANGPTL3/EL pathway in mediating VLDL remnant particle clearance and LDL-C lowering.10”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [10]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Efficient Bayesian mixed-model analysis increases association power in large cohorts
Loh, P.-R., Tucker, G., Bulik-Sullivan, B. K., Vilhjálmsson, B. J., Finucane, H. K., Salem, R. M., Chasman, D. I., Ridker, P. M., Neale, B. M., Berger, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3190 · Cited by 1,507
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M., & Maeda, N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4471 · Cited by 944
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · cited 4×
“Pharmacological inhibition of ANGPTL3 replicates the phenotype of individuals with ANGPTL3 LOF mutations (6, 7) and lowers plasma lipids in mice, monkeys, and humans (9–11).”
InfluentialSelf-citationKowal, R. C., Herz, J., Goldstein, J. L., Esser, V, & Brown, M. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5810 · Cited by 595
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis
Valenzuela, D. M., Murphy, A. J., Frendewey, D., Gale, N. W., Economides, A. N., Auerbach, W., Poueymirou, W. T., Adams, N. C., Rojas, J., Yasenchak, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt822 · Cited by 584
Self-citation
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“76 The preceding discussion illustrates the difficulty inherent in defining remnants.”
BackgroundEvinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
“Furthermore, inhibition of ANGPTL3 reduces VLDL lipid content and size in an endothelial lipase-dependent manner [41].”
BackgroundInhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion
Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., et al. (2022) · Nature · doi:10.1038/s41586-022-05006-3 · Cited by 188
Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Metadata
- Authors
- Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., Van Hout, C., Gromada, J., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V.
- Affiliations
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gusarova, Viktoria
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 61
- Issue
- 9
- Pages
- 1271-1286
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC7469887
- OpenAlex
- W3041635484
- Cited by
- 208
- References
- 69
- Citations by year
- 2026: 34 · 2025: 28 · 2024: 36 · 2023: 29 · 2022: 33 · 2021: 42 · 2020: 6
- FWCI
- 17.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 80 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (P01HL020948)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, endothelial lipase, VLDL clearance, LDL cholesterol, VLDL remnants, hypercholesterolemia, lipoprotein metabolism, lipidomics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Animals, Female, Humans, Lipase, Cholesterol, LDL, Lipoproteins, VLDL, Male, Receptors, LDL, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. https://app.cochat.ai/papers/10.1194/jlr.ra120000888
- The paper
- Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., Van Hout, C., Gromada, J., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V. (2020). Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. Journal of Lipid Research. https://doi.org/10.1194/jlr.ra120000888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.